利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

34 条记录 (耗时 0.043 秒)

    Oral insulin therapies and protocol
    1.
    发明授权
    Oral insulin therapies and protocol 有权
    口服胰岛素治疗和方案

    公开(公告)号：US08324156B2

    公开(公告)日：2012-12-04

    申请号：US12546283

    申请日：2009-08-24

    申请人： Ehud Arbit ,  Michael Goldberg ,  Shingal Majuru

    发明人： Ehud Arbit ,  Michael Goldberg ,  Shingal Majuru

    IPC分类号： A61K38/28

    CPC分类号： A61K38/28 ,  A61B5/14532 ,  A61K31/192 ,  A61K38/00

    摘要： Methods for treating impaired glucose tolerance and early and late stage diabetes in mammals, for prophylactically sparing β-cell function, aiding in preventing β-cell death, preventing the onset of overt diabetes in a mammal with type 2 diabetes, treating the current level of glycemic control dysfunction of a mammal with impaired glucose tolerance or diabetes, comprising orally administering insulin and a delivery agent that facilitates insulin absorption from the gastrointestinal tract at the time of or shortly before mealtime, e.g., within about 10 minutes prior to ingestion of a meal, on a chronic basis. The methods also comprise, in addition to administering a rapid-acting insulin to provide a first insulin peak, administering a slow acting insulin to provide a second insulin peak occurring at a later time but of a longer duration. These methods achieve improved glycemic control without the risks of hypoglycemia, hyperinsulinemia and weight gain and the need for frequent blood glucose monitoring that are normally associated with insulin therapy.

    摘要翻译： 用于治疗哺乳动物葡萄糖耐量异常和早期和晚期糖尿病的方法，用于预防性保护和细胞功能，有助于预防和细胞死亡，预防2型糖尿病哺乳动物的明显糖尿病发作，治疗目前的 包括葡萄糖耐量降低或糖尿病患者的血糖控制功能障碍的水平，包括口服给药胰岛素和促进胰岛素在进食之前或之后的胰岛素从胃肠道吸收的递送剂，例如在摄取前约10分钟内 一顿饭，慢性的。 除了施用快速作用的胰岛素以提供第一胰岛素峰之外，所述方法还包括施用缓慢作用的胰岛素以提供在稍后时间但持续时间更长的时间发生的第二胰岛素峰。 这些方法可以改善血糖控制，没有低血糖，高胰岛素血症和体重增加的风险，以及通常与胰岛素治疗相关的频繁血糖监测的需要。

    Night-time oral insulin therapy
    4.
    发明申请
    Night-time oral insulin therapy 有权
    夜间口服胰岛素治疗

    公开(公告)号：US20060178296A1

    公开(公告)日：2006-08-10

    申请号：US10541433

    申请日：2004-01-06

    申请人： Michael Goldberg ,  Ehud Arbit

    发明人： Michael Goldberg ,  Ehud Arbit

    IPC分类号： A61K38/28

    CPC分类号： A61K38/28

    摘要： A method for protection of a mammal that has impaired glucose tolerance or early stage diabetes mellitus from developing overt or insulin dependent diabetes comprises administering an orally effective dose of a pharmaceutical formulation comprising insulin at nighttime, e.g., at or shortly before bedtime.

    摘要翻译： 保护具有葡萄糖耐量降低或糖尿病早期受损的哺乳动物从发展明显或胰岛素依赖性糖尿病的方法包括在夜间，例如在睡前或在就寝时间之前施用口服有效剂量的包含胰岛素的药物制剂。

    Oral insulin therapy
    5.
    发明申请
    Oral insulin therapy 有权
    口服胰岛素治疗

    公开(公告)号：US20060234913A1

    公开(公告)日：2006-10-19

    申请号：US10500822

    申请日：2003-01-07

    申请人： Ehud Arbit ,  Richat Abbas ,  Michael Goldberg ,  T. Woods ,  Steven Dinh ,  Vivien Wong

    发明人： Ehud Arbit ,  Richat Abbas ,  Michael Goldberg ,  T. Woods ,  Steven Dinh ,  Vivien Wong

    IPC分类号： A61K38/28 ,  A61K31/195

    CPC分类号： A61K47/18 ,  A61K9/2013 ,  A61K9/4858 ,  A61K38/28 ,  A61K2300/00

    摘要： Pharmaceutical dosage forms for oral administration to a patient for the treatment of diabetes, comprising insulin and a delivery agent that facilitates insulin transport in a therapeutically effective amount to the bloodstream and that result in a lower incidence of vascular diseases associated with the repeated administration of insulin are disclosed. Also disclosed is a method of attenuating the undesirable incidence of diseases associated with chronic dosing of insulin is provided whereby the oral administration to a patient of insulin along with a suitable delivery agent that facilitates the absorption of insulin from the gastrointestinal tract of the patient in a therapeutically effective amount, for treatment of diabetes.

    摘要翻译： 用于口服给予患者用于治疗糖尿病的药物剂型，其包含胰岛素和促进胰岛素以治疗有效量转运至血液并导致与重复施用胰岛素相关的血管疾病的较低发生率的递送剂 被披露。 还公开了一种减轻与慢性给药胰岛素相关的疾病的不期望的发病率的方法，其中通过口服给予胰岛素患者以及促进从患者的胃肠道吸收胰岛素的合适的递送剂 治疗有效量，用于治疗糖尿病。

    Oral insulin therapies and protocol
    6.
    发明授权
    Oral insulin therapies and protocol 有权
    口服胰岛素治疗和方案

    公开(公告)号：US08729016B2

    公开(公告)日：2014-05-20

    申请号：US12485521

    申请日：2009-06-16

    申请人： Ehud Arbit ,  Michael Goldberg ,  Shingai Majuru

    发明人： Ehud Arbit ,  Michael Goldberg ,  Shingai Majuru

    IPC分类号： A61K38/28

    CPC分类号： A61K38/28 ,  A61B5/14532 ,  A61K31/192 ,  A61K38/00

    摘要： Methods for treating impaired glucose tolerance and early and late stage diabetes in mammals, for prophylactically sparing β-cell function, aiding in preventing β-cell death, preventing the onset of overt diabetes in a mammal with type 2 diabetes, treating the current level of glycemic control dysfunction of a mammal with impaired glucose tolerance or diabetes, comprising orally administering insulin and a delivery agent that facilitates insulin absorption from the gastrointestinal tract at the time of or shortly before mealtime, e.g., within about 10 minutes prior to ingestion of a meal, on a chronic basis. The methods also comprise, in addition to administering a rapid-acting insulin to provide a first insulin peak, administering a slow acting insulin to provide a second insulin peak occurring at a later time but of a longer duration. These methods achieve improved glycemic control without the risks of hypoglycemia, hyperinsulinemia and weight gain and the need for frequent blood glucose monitoring that are normally associated with insulin therapy.

    摘要翻译： 用于治疗哺乳动物葡萄糖耐量异常和早期和晚期糖尿病的方法，用于预防性保护和细胞功能，有助于预防和细胞死亡，预防2型糖尿病哺乳动物的明显糖尿病发作，治疗目前的 包括葡萄糖耐量降低或糖尿病患者的血糖控制功能障碍的水平，包括口服给药胰岛素和促进胰岛素在进食之前或之后的胰岛素从胃肠道吸收的递送剂，例如在摄取前约10分钟内 一顿饭，慢性的。 除了施用快速作用的胰岛素以提供第一胰岛素峰之外，所述方法还包括施用缓慢作用的胰岛素以提供在稍后时间但持续时间更长的时间发生的第二胰岛素峰。 这些方法可以改善血糖控制，没有低血糖，高胰岛素血症和体重增加的风险，以及通常与胰岛素治疗相关的频繁血糖监测的需要。

    Oral insulin therapy
    7.
    发明授权
    Oral insulin therapy 有权
    口服胰岛素治疗

    公开(公告)号：US07429564B2

    公开(公告)日：2008-09-30

    申请号：US10500822

    申请日：2003-01-07

    申请人： Ehud Arbit ,  Richat Abbas ,  Michael Goldberg ,  T. Cooper Woods ,  Steven Dinh ,  Vivien Wong

    发明人： Ehud Arbit ,  Richat Abbas ,  Michael Goldberg ,  T. Cooper Woods ,  Steven Dinh ,  Vivien Wong

    IPC分类号： A61K38/28

    CPC分类号： A61K47/18 ,  A61K9/2013 ,  A61K9/4858 ,  A61K38/28 ,  A61K2300/00

    摘要： Pharmaceutical dosage forms for oral administration to a patient for the treatment of diabetes, comprising insulin and a delivery agent that facilitates insulin transport in a therapeutically effective amount to the bloodstream and that result in a lower incidence of vascular diseases associated with the repeated administration of insulin are disclosed. Also disclosed is a method of attenuating the undesirable incidence of diseases associated with chronic dosing of insulin is provided whereby the oral administration to a patient of insulin along with a suitable delivery agent that facilitates the absorption of insulin from the gastrointestinal tract of the patient in a therapeutically effective amount, for treatment of diabetes.

    摘要翻译： 用于口服给予患者用于治疗糖尿病的药物剂型，其包含胰岛素和促进胰岛素以治疗有效量转运至血液并导致与重复施用胰岛素相关的血管疾病的较低发生率的递送剂 被披露。 还公开了一种减轻与慢性给药胰岛素相关的疾病的不期望的发病率的方法，其中通过口服给予胰岛素患者以及促进从患者的胃肠道吸收胰岛素的合适的递送剂 治疗有效量，用于治疗糖尿病。

    ORAL INSULIN THERAPIES AND PROTOCOL
    8.
    发明申请
    ORAL INSULIN THERAPIES AND PROTOCOL 审中-公开
    口服胰岛素治疗和协议

    公开(公告)号：US20080175907A1

    公开(公告)日：2008-07-24

    申请号：US12040293

    申请日：2008-02-29

    申请人： Ehud Arbit ,  Michael Goldberg ,  Shingai Majuru

    发明人： Ehud Arbit ,  Michael Goldberg ,  Shingai Majuru

    IPC分类号： A61K9/20 ,  A61K38/28 ,  A61P3/10

    CPC分类号： A61K38/28 ,  A61B5/14532 ,  A61K31/192 ,  A61K38/00

    摘要： Methods for treating impaired glucose tolerance and early and late stage diabetes in mammals, for prophylactically sparing β-cell function, aiding in preventing β-cell death, preventing the onset of overt diabetes in a mammal with type 2 diabetes, treating the current level of glycemic control dysfunction of a mammal with impaired glucose tolerance or diabetes, comprising orally administering insulin and a delivery agent that facilitates insulin absorption from the gastrointestinal tract at the time of or shortly before mealtime, e.g., within about 10 minutes prior to ingestion of a meal, on a chronic basis. The methods also comprise, in addition to administering a rapid-acting insulin to provide a first insulin peak, administering a slow acting insulin to provide a second insulin peak occurring at a later time but of a longer duration. These methods achieve improved glycemic control without the risks of hypoglycemia, hyperinsulinemia and weight gain and the need for frequent blood glucose monitoring that are normally associated with insulin therapy.

    摘要翻译： 用于治疗哺乳动物葡萄糖耐量异常和早期和晚期糖尿病的方法，用于预防性节省β-细胞功能，有助于预防β-细胞死亡，预防2型糖尿病哺乳动物的明显糖尿病发作，治疗目前的水平 具有葡萄糖耐量降低或糖尿病的哺乳动物的血糖控制功能障碍，包括在摄食之前或之后约10分钟内口服胰岛素和促进胰岛素从胃肠道吸收的输送剂 ，长期的。 除了施用快速作用的胰岛素以提供第一胰岛素峰之外，所述方法还包括施用缓慢作用的胰岛素以提供在稍后时间但持续时间更长的时间发生的第二胰岛素峰。 这些方法可以改善血糖控制，没有低血糖，高胰岛素血症和体重增加的风险，以及通常与胰岛素治疗相关的频繁血糖监测的需要。

    Antidiabetic oral insulin-biguanide combination
    10.
    发明申请
    Antidiabetic oral insulin-biguanide combination 审中-公开
    抗糖尿病口服胰岛素双胍组合

    公开(公告)号：US20100048454A1

    公开(公告)日：2010-02-25

    申请号：US11632808

    申请日：2005-08-03

    申请人： Ehud Arbit ,  Steven Dinh ,  Michael Goldberg

    发明人： Ehud Arbit ,  Steven Dinh ,  Michael Goldberg

    IPC分类号： A61K38/28 ,  A61P3/10

    CPC分类号： A61K38/28 ,  A61K31/155 ,  A61K2300/00

    摘要： Pharmaceutical dosage forms, comprising insulin, a delivery agent that facilitates insulin transport in a therapeutically effective amount to the bloodstream and a biguanide, such as metformin, are disclosed for oral administration to a patient for the treatment of diabetes. Also disclosed are methods for achieving improved glucose tolerance and glycemic control in a diabetic mammal without any statistically significant increase in weight, risk of hypoglycemia or hyperinsulinemia, and the need for monitoring blood glucose concentrations or HbAlc levels, and methods for reducing the incidence and/or severity of one or more disease states associated with chronic dosing of insulin; for prophylactically sparing (3-cell function or for preventing (3-cell death or dysfunction in a mammal with impaired glucose tolerance or early stage diabetes mellitus; and for long-term protection from developing (or delaying the onset of) overt or insulin dependent diabetes in a mammal with impaired glucose tolerance or early stage diabetes.

    摘要翻译： 公开了包括胰岛素，促进胰岛素以治疗有效量转运至血液的递送剂和双胍，例如二甲双胍的药物剂型，用于口服给患者治疗糖尿病。 还公开了用于在糖尿病哺乳动物中实现改善的葡萄糖耐量和血糖控制的方法，而没有任何统计学显着的重量增加，低血糖或高胰岛素血症的风险，以及监测血糖浓度或HbAlc水平的需要，以及用于降低发生率和/ 或与慢性给药胰岛素相关的一种或多种疾病状态的严重程度; 用于预防性保护（3细胞功能或用于预防（葡萄糖耐量降低或早期糖尿病）的哺乳动物中的3细胞死亡或功能障碍;以及用于长期保护以发展（或延迟发作）明显或胰岛素依赖性 具有葡萄糖耐量降低或早期糖尿病的哺乳动物的糖尿病。